Attached files
| file | filename |
|---|---|
| EX-10.15 - EX-10.15 - Vera Therapeutics, Inc. | d96328dex1015.htm |
| EX-10.14 - EX-10.14 - Vera Therapeutics, Inc. | d96328dex1014.htm |
| EX-10.13 - EX-10.13 - Vera Therapeutics, Inc. | d96328dex1013.htm |
| EX-10.12 - EX-10.12 - Vera Therapeutics, Inc. | d96328dex1012.htm |
| EX-10.11 - EX-10.11 - Vera Therapeutics, Inc. | d96328dex1011.htm |
| EX-10.10 - EX-10.10 - Vera Therapeutics, Inc. | d96328dex1010.htm |
| EX-10.9 - EX-10.9 - Vera Therapeutics, Inc. | d96328dex109.htm |
| EX-10.2 - EX-10.2 - Vera Therapeutics, Inc. | d96328dex102.htm |
| EX-10.1 - EX-10.1 - Vera Therapeutics, Inc. | d96328dex101.htm |
| EX-4.2 - EX-4.2 - Vera Therapeutics, Inc. | d96328dex42.htm |
| EX-3.3 - EX-3.3 - Vera Therapeutics, Inc. | d96328dex33.htm |
| EX-3.1 - EX-3.1 - Vera Therapeutics, Inc. | d96328dex31.htm |
| S-1 - S-1 - Vera Therapeutics, Inc. | d96328ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Vera Therapeutics, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
| /s/ KPMG LLP |
| San Francisco, California April 23, 2021 |